These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28701190)

  • 41. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
    Hynninen J; Lavonius M; Oksa S; Grénman S; Carpén O; Auranen A
    Gynecol Oncol; 2013 Feb; 128(2):229-32. PubMed ID: 23142076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
    Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
    Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
    Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.
    Philip CA; Pelissier A; Bonneau C; Hequet D; Rouzier R; Pouget N
    Anticancer Res; 2016 Sep; 36(9):4865-71. PubMed ID: 27630342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
    Merlo S; Besic N; Drmota E; Kovacevic N
    Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
    Worley MJ; Guseh SH; Rauh-Hain JA; Williams KA; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?
    Vizzielli G; Fanfani F; Chiantera V; Tortorella L; Lucidi A; Petrillo M; Costantini B; Scambia G; Fagotti A
    Anticancer Res; 2015 May; 35(5):3027-32. PubMed ID: 25964591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in regional diagnostic strategies and in intended versus actual first-line treatment of patients with advanced ovarian cancer in Denmark.
    Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Sogaard CH; Hoegdall C
    Int J Gynecol Cancer; 2014 Sep; 24(7):1195-205. PubMed ID: 25101855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
    Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
    Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
    Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
    Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.
    Lv X; Cui S; Zhang X; Ren C
    J Gynecol Oncol; 2020 Mar; 31(2):e12. PubMed ID: 31912670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.